About

Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction.  As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals. 

Our lead asset, PDP-716, is a once-daily brimonidine for ocular hypertension and open angle glaucoma. The NDA submission was accepted with a PDUFA target action date of August 4, 2023.  

Our next asset, SDN-037, is a twice daily topical difluprednate for post-surgical inflammation and pain.  Each product utilizes a unique, proprietary, extended release technology that is patent protected through at least 2036.

PDP-716, SDN-037, and TearActTM delivery technology were licensed by Visiox from Sun Pharma Advanced Research Company Ltd.